Trial · NCT02259582
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Placebo/Placebo Arm (Arm 1) | Complete response (CR) | 0 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Placebo Arm (Arm 2) | Complete response (CR) | 0 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Demcizumab Arm (Arm 3) | Complete response (CR) | 0 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Placebo/Placebo Arm (Arm 1) | Partial response (PR) | 13 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Placebo Arm (Arm 2) | Partial response (PR) | 10 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Demcizumab Arm (Arm 3) | Partial response (PR) | 6 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Placebo/Placebo Arm (Arm 1) | Stable disease (SD) | 10 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Placebo Arm (Arm 2) | Stable disease (SD) | 14 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Demcizumab Arm (Arm 3) | Stable disease (SD) | 15 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Placebo/Placebo Arm (Arm 1) | Progressive disease (PD) | 2 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Placebo Arm (Arm 2) | Progressive disease (PD) | 4 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Demcizumab Arm (Arm 3) | Progressive disease (PD) | 5 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Placebo/Placebo Arm (Arm 1) | Not evaluable (NE) | 0 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Placebo Arm (Arm 2) | Not evaluable (NE) | 0 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Demcizumab Arm (Arm 3) | Not evaluable (NE) | 0 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Placebo/Placebo Arm (Arm 1) | Missing | 0 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Placebo Arm (Arm 2) | Missing | 0 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Demcizumab Arm (Arm 3) | Missing | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02259582/results